Takemura J, Seino Y, Tsuda K, Seino S, Ikeda M, Sakurai H, Imura H
Endocrinol Jpn. 1981 Feb;28(1):17-21. doi: 10.1507/endocrj1954.28.17.
The response to plasma immunoreactive gastric inhibitory polypeptide (GIP) to oral glucose loading was determined in 10 normal subjects, 10 patients with mild diabetes mellitus, and 10 patients with moderate to severe diabetes mellitus. In normal subjects the mean fasting GIP was 167 +/- 17 pg/ml which rose significantly after glucose loading, reaching the peak value of 513 +/- 44 pg/ml at 30 min. In mild diabetic patients, fasting plasma GIP was not significantly different from that in normal subjects. However, the mean peak GIP level following glucose loading was 683 +/- 71 pg/ml, significantly higher than that in normal subjects (p less than 0.05). In moderate and severe diabetics, oral glucose loading caused an abrupt rise in plasma GIP from the basal level of 304 +/- 31 pg/ml to the peak of 870 +/- 63 pg/ml occurring at 30 min, both of which were significantly higher than the corresponding values in normal subjects (p less than 0.01). These results suggest that GIP response to oral glucose loading is enhanced in diabetic patients in proportion to the degree of their glucose intolerance.
对10名正常受试者、10名轻度糖尿病患者和10名中度至重度糖尿病患者测定了口服葡萄糖负荷后血浆免疫反应性胃抑制多肽（GIP）的反应。正常受试者空腹GIP平均值为167±17 pg/ml，葡萄糖负荷后显著升高，在30分钟时达到峰值513±44 pg/ml。轻度糖尿病患者空腹血浆GIP与正常受试者无显著差异。然而，葡萄糖负荷后GIP平均峰值水平为683±71 pg/ml，显著高于正常受试者（p<0.05）。在中度和重度糖尿病患者中，口服葡萄糖负荷使血浆GIP从基础水平304±31 pg/ml急剧升至30分钟时的峰值870±63 pg/ml，两者均显著高于正常受试者的相应值（p<0.01）。这些结果表明，糖尿病患者对口服葡萄糖负荷的GIP反应与他们的葡萄糖不耐受程度成比例增强。
